Drug Trial Radar · NCT05425602
A Study of MAX-40279combined With KN046 in Patients With Advanced / Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jun 21, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
108
Planned (sponsor's estimate)
Start
Jul 31, 2022
Primary completion
Dec 30, 2023
Study completion Dec 30, 2024
Sponsor
- Lead sponsor
- Maxinovel Pty., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 21, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This include two parts, Stage 1 is a dose climbing study and Stage 2 is a dose extending study.
Conditions
- Advanced / Metastatic Solid Tumors
Interventions
MAX-40279-01: 50mg/70mgDrug
\[Stage 1\]The starting dose of MAX-40279 was 35 mg BID, and three dose levels were initially set: 35 mg, 50 mg, and 70 mg administered twice daily (BID) continuously, and the dose of KN046 was 5 mg/kg as a fixed dose administered every 3 weeks. \[Stage 2\]When the RP2D dose is obtained in the dose-finding phase, the trial will enter the dose expansion phase.
Primary outcomes
What the sponsor says the trial is designed to measure.
- DLTTime frame: through study Stage1 completion,an average of 6 months
- Maximum Tolerated Dose (MTD) or Recommended Phase 2 Dose (RP2D)Time frame: through study Stage1 completion,an average of 6 months
- ORRTime frame: through study Stage2 completion,an average of 24 months
- PFSTime frame: through study Stage2 completion,an average of 24 months
- Adverse events (AEs), serious adverse events (SAEs)Time frame: through study Stage2 completion,an average of 24 months
- laboratory testsTime frame: through study Stage2 completion,an average of 24 months
- vital signsTime frame: through study Stage2 completion,an average of 24 months
- 12 ECGTime frame: through study Stage2 completion,an average of 24 months
- physical examination abnormalitiesTime frame: through study Stage2 completion,an average of 24 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.